1. Search Result
Search Result
Results for "

DFO

" in MedChemExpress (MCE) Product Catalog:

5

Inhibitors & Agonists

1

Fluorescent Dyes

1

Biochemical Assay Reagents

1

Inhibitory Antibodies

2

Click Chemistry

Cat. No. Product Name Target Research Areas Chemical Structure
  • HY-B0988
    Deferoxamine mesylate
    395+ Cited Publications

    Desferrioxamine B mesylate; DFOM

    Autophagy HIF/HIF Prolyl-Hydroxylase Reactive Oxygen Species (ROS) Apoptosis Akt Infection Neurological Disease Metabolic Disease Inflammation/Immunology Cancer
    Deferoxamine mesylate (Deferoxamine B mesylate) is an iron chelator (binds to Fe(III) and many other metal cations), is widely used to reduce iron accumulation and deposition in tissues. Deferoxamine mesylate upregulates HIF-1α levels with good antioxidant activity. Deferoxamine mesylate also shows anti-proliferative activity, can induce apoptosis and autophagy in cancer cells. Deferoxamine mesylate can be used in studies of diabetes, neurodegenerative diseases as well as anti-cancer and anti-COVID-19 .
    Deferoxamine mesylate
  • HY-D0903
    1,8-Diazafluoren-9-one
    5+ Cited Publications

    DFO

    Fluorescent Dye Others
    1,8-Diazafluoren-9-one (DFO) is a chemical that is used to find fingerprints on porous surfaces. 1,8-Diazafluoren-9-one reacts with amino acids present in the fingerprint to form highly fluorescent derivatives (Ex/Em = ~470/570).
    1,8-Diazafluoren-9-one
  • HY-158067

    DFO-DBCO

    Biochemical Assay Reagents Radionuclide-Drug Conjugates (RDCs) Cancer
    Deferoxamine-DBCO is a bifunctional chelating agent. Deferoxamine-DBCO efficiently chelates with radioactive metals (such as 89Zr) through the DFO structure to achieve radiolabeling. Deferoxamine-DBCO undergoes a metal-free Huisgen cycloaddition reaction with azide-containing biomolecules (such as siRNA, monoclonal antibodies) under bioorthogonal conditions through the DBCO structure to achieve targeted coupling. Deferoxamine-DBCO has efficient metal chelating ability and specific bioorthogonal reaction activity. Deferoxamine-DBCO can be used for targeted radioactive imaging studies of tumors .
    Deferoxamine-DBCO
  • HY-170749

    Drug Intermediate Others
    DFO-BCN is a drug intermediate, that can be used for synthesis of PET/CT imaging agent DFO-CPC634 through click chemistry .
    DFO-BCN
  • HY-P992341

    MMP Cancer
    D8P1C1 is a high-affinity ADAM17 inhibitor (with a Kd of 180 pM targeting ADAM17-ECD) that reduces the shedding and phosphorylation of EGFR ligands. D8P1C1 inhibits cancer cell proliferation in vitro and tumor growth in xenograft models. 89Zr-DFO-D8P1C1 radioimmunological PET imaging shows its substantial accumulation in ovarian tumor xenografts, serving as a platform for generating bispecific T-cell engager derivatives. D8P1C1 can be applied to research on related diseases including triple-negative breast cancer, various types of ovarian cancer, lung adenocarcinoma, glioma, and colon cancer .
    D8P1C1

Inquiry Online

Your information is safe with us. * Required Fields.

Salutation

 

Country or Region *

Applicant Name *

 

Organization Name *

Department *

     

Email Address *

 

Product Name *

Cat. No.

 

Requested quantity *

Phone Number *

     

Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent: